TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04155242

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cytosponge test
Description: The Cytosponge will be administered by the study nurse prior to the participant having the endoscopy, usually as part of the same visit to hospital. The capsule along with the string is swallowed by drinking a small glass of water. The participant is asked to hold the Cytosponge in situ for 5 minutes. The sponge contained within expands and is then drawn back by the research nurse up the oesophagus by the attached string, collecting cells as it moves upwards. This device received a letter of no objection by the MHRA for use in the BEST pilot trial (LRQ 0939857) but it is not CE marked. Cytosponge and research endoscopic biopsies will be couriered to the Fitzgerald laboratory, at the MRC Cancer Cell Unit on a regular basis. The specimens will be processed in conjunction with the Cambridge University Hospitals' NHS Foundation Trust tissue bank which is accredited to GLP standards.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Assessment of the panel of molecular biomarkers: IM-SCORE, TFF3 protein expression, methylation panel, p53 mutation
Description: Molecular analysis of the specimen obtained by Cytosponge or endoscopic biopsies - TFF3 protein expression, methylation panel, p53 mutation. Endoscopic biopsies will be assessed for the presence of IM (according to the IM-score).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Oesophagogastroduodenoscopy
Description: * Endoscopy will be carried out with white light and NBI with optical magnification or near focus to inspect oesophagus and GOJ.~* NBI magnification will be used to assess systematically the mucosal pit pattern at the GOJ and to look for light blue crest (LBC) sign.~* Targeted biopsies will be taken from either areas with LBC or irregular pit pattern on NBI, followed by random biopsies as per clinical standard. A maximum of 6 biopsies will be taken at the GOJ (maximum 4 targeted and 4 random.. During the first 2 post RFA follow up, at discretion of the endoscopists, neo-suqamous biopsies can be taken in line with local policies.~* Argon plasma coagulation ablation is allowed in a single island up to 5mm or up to 3 islands \<3mm within the study endoscopy as long as this does not represent an obstacle to GOJ biopsies.
Study: NCT03697889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen sodium (test product)
Description: Participants will be administered single doses of 275 mg Naproxen sodium (test product) tablet orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen sodium (test product)
Description: Participants will be administered single doses of 275 mg Naproxen sodium (test product) tablet orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen sodium (reference product)
Description: Participants will be administered single doses of 275 mg Naproxen sodium (reference product - Nalgesin) tablet orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen sodium (reference product)
Description: Participants will be administered single doses of 275 mg Naproxen sodium (reference product - Nalgesin) tablet orally.
Study: NCT04363788

Intervention type: PROCEDURE
Intervention: double gloves
Description: The study was based on dying gloves used during resuscitation. The gloves were secured with disposable hermetically sealed pouches and described by one of the EMS team members - each time after resuscitation was completed.
Study: NCT02935283

Intervention type: PROCEDURE
Intervention: MRI
Description: MRI, fMRI, 1H MRS, DTI

Intervention type: PROCEDURE
Intervention: MRI
Description: MRI, fMRI, 1H MRS, DTI

Intervention type: PROCEDURE
Intervention: MRI
Description: MRI, fMRI, 1H MRS, DTI
Study: NCT01828931

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: A lifestyle intervention (LI) aimed at reducing caloric intake and increasing physical activity

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Care as usual
Study: NCT01819779

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exforge tab. 10/160mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lodivixx tab. 5/160mg
Study: NCT02836015

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shared Medical Visit
Description: The Shared Medical Visits are a replacement for standard diabetic visits with PCP, and will occur completely in Spanish, the patients' preferred primary language. An interdisciplinary group including behavioral health, social work, pharmacy, MD, and diabetic educator will be involved in the visit. The focal point of the meeting is a 30 minute session in which all members are seated around a large table in the Midtown SMV area and each patient's blood sugars, labs, and medications are discussed in front of the entire group. Pertinent labs and vaccines are drawn/administered.
Study: NCT03442673

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: Stimulation with vinorelbine together with G-CSF for mobilization of autologous stem cells

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Stimulation with gemcitabine together with G-CSF for mobilization of autologous stem cells

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF
Description: Cytokine stimulation with G-CSF for mobilization of autologous stem cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Cytokine stimulation with G-CSF for mobilization of autologous stem cells
Study: NCT04110665

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Tramadol 100 mg tablet
Study: NCT02935283

Intervention type: PROCEDURE
Intervention: MRI
Description: MRI, fMRI, 1H MRS, DTI

Intervention type: BEHAVIORAL
Intervention: Behavioral
Description: Battery of executive function tasks

Intervention type: BEHAVIORAL
Intervention: Behavioral
Description: Battery of executive function tasks

Intervention type: BEHAVIORAL
Intervention: Behavioral
Description: Battery of executive function tasks

Intervention type: BEHAVIORAL
Intervention: Behavioral
Description: Battery of executive function tasks
Study: NCT02802917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPF 50 Y49 091 (BAY 987516)
Description: 5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPF 50 X15 158 (BAY 987516)
Description: 5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPF 50 X15 160 (BAY 987516)
Description: 5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPF 50 X57 162 (BAY 987516)
Description: 5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: J & J baby shampoo, X46 046 (control)
Description: 5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: J & J baby shampoo, X46 046 (control)
Description: 5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: J & J baby shampoo, X46 046 (control)
Description: 5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: J & J baby shampoo, X46 046 (control)
Description: 5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.
Study: NCT02365233

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DPP4 inhibitor
Description: Comparison between three common alternative therapeutic strategies to improve glycemic control in patients with type 2 diabetes who are not controlled with metformin alone.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Comparison between three common alternative therapeutic strategies to improve glycemic control in patients with type 2 diabetes who are not controlled with metformin alone.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lantus insulin
Description: Comparison between three common alternative therapeutic strategies to improve glycemic control in patients with type 2 diabetes who are not controlled with metformin alone.
Study: NCT04934917

Intervention type: DEVICE
Intervention: Magnetic Resonance Imaging
Description: Magnetic Resonance Imaging. Pain testing: Temporal summation, Pain thresholds. Assessment of symptoms: Questionnaires. All interventions are made at baseline only (1 time/subject).

Intervention type: DEVICE
Intervention: Magnetic Resonance Imaging
Description: Magnetic Resonance Imaging. Pain testing: Temporal summation, Pain thresholds. Assessment of symptoms: Questionnaires. All interventions are made at baseline only (1 time/subject).
Study: NCT00986297

Intervention type: RADIATION
Group type: OTHER
Intervention: hypofractionated radiation therapy
Description: hypofractionated radiation therapy
Study: NCT03277235

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resilience model-based total care plan
Description: 12-week care plan with 5 times face-to-face intervention and weekly phone call follow-up to increase the protective factors (positive thinking. problem-solving, finding meaning, and social connection) and decrease the risk factors (disease-related distress and defense coping) of resilience
Study: NCT02459288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel first
Description: After randomization, 2 weeks Clopidogrel (Plavix) 75 mg QD will be given and then crossover with following 2 weeks Ticagrelor (Brilinta) 90 mg bd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor first
Description: After randomization, 2 weeks Ticagrelor (Brilinta) 90 mg bd will be given then crossover with following 2 weeks Clopidogrel (Plavix) 75 mg QD
Study: NCT03618290

Intervention type: DIAGNOSTIC_TEST
Intervention: Analyze plasma free fatty acid in blood
Description: This study is prospectively designed with the purpose of investigating potential new lipid targets and the free fatty acids as specific markers of acute brain injury.~Dynamic measurement of lipid profile in 3 consecutive samples at (I) the time intervals of admission, (II) 8 hours and (III) 24 hours after admission will give the opportunity of comparison mass-spectrometric analysis of highly complex plasma samples thus reducing variability between analyzed samples and allowing precise focusing on essential lipid target changes during stroke progression.

Intervention type: DIAGNOSTIC_TEST
Intervention: Analyze plasma free fatty acid in blood
Description: This study is prospectively designed with the purpose of investigating potential new lipid targets and the free fatty acids as specific markers of acute brain injury.~Dynamic measurement of lipid profile in 3 consecutive samples at (I) the time intervals of admission, (II) 8 hours and (III) 24 hours after admission will give the opportunity of comparison mass-spectrometric analysis of highly complex plasma samples thus reducing variability between analyzed samples and allowing precise focusing on essential lipid target changes during stroke progression.

Intervention type: DIAGNOSTIC_TEST
Intervention: Analyze plasma free fatty acid in blood
Description: This study is prospectively designed with the purpose of investigating potential new lipid targets and the free fatty acids as specific markers of acute brain injury.~Dynamic measurement of lipid profile in 3 consecutive samples at (I) the time intervals of admission, (II) 8 hours and (III) 24 hours after admission will give the opportunity of comparison mass-spectrometric analysis of highly complex plasma samples thus reducing variability between analyzed samples and allowing precise focusing on essential lipid target changes during stroke progression.
Study: NCT02081885

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tricalcium Phosphate / Chitosan

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Graft
Study: NCT00529607

Intervention type: DRUG
Intervention: contrast echocardiography
Description: directly after PCI, at 24 h after PCI, before discharge and at 6 months

Intervention type: PROCEDURE
Intervention: 2D and 3D echocardiography
Description: directly after PCI, at 24 h after PCI, before discharge and at 6 months

Intervention type: PROCEDURE
Intervention: cardiac MRI
Description: before discharge and after 6 months

Intervention type: PROCEDURE
Intervention: blood sampling
Description: routine lab work plus infarction and inflammation biomarkers~1: before PCI, after PCI, at 34 hours, at discharge, at 6 months 2 and 3: one blood sample in total before PCI in 2 and at any time in 3

Intervention type: PROCEDURE
Intervention: blood sampling
Description: routine lab work plus infarction and inflammation biomarkers~1: before PCI, after PCI, at 34 hours, at discharge, at 6 months 2 and 3: one blood sample in total before PCI in 2 and at any time in 3

Intervention type: PROCEDURE
Intervention: blood sampling
Description: routine lab work plus infarction and inflammation biomarkers~1: before PCI, after PCI, at 34 hours, at discharge, at 6 months 2 and 3: one blood sample in total before PCI in 2 and at any time in 3
Study: NCT00225264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone 15 mg titrated up to 45 mg, tablets, orally, once daily and glimepiride placebo-matching capsules, orally, once daily for up to 72 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Pioglitazone placebo-matching tablets, orally, once daily and glimepiride 1 mg titrated up to 4 mg, capsules, orally, once daily for up to 72 weeks.
Study: NCT01087788

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CZP 200 mg Q2W
Description: 200 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 2 weeks (Q2W).

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: CZP 200 mg Q2W
Description: 200 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 2 weeks (Q2W).

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: CZP 200 mg Q2W
Description: 200 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 2 weeks (Q2W).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CZP 400 mg Q4W
Description: 400 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 4 weeks (Q4W).

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: CZP 400 mg Q4W
Description: 400 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 4 weeks (Q4W).

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: CZP 400 mg Q4W
Description: 400 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 4 weeks (Q4W).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo to CZP injection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo to CZP injection.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo to CZP injection.

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Matching Placebo to CZP injection.

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Matching Placebo to CZP injection.

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Matching Placebo to CZP injection.

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Matching Placebo to CZP injection.
Study: NCT03159962

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bonded RME (Rapid Maxillary Expander) appliance
Description: The expansion screw was activated 1 quarter of a turn per day (0.25 mm per turn) until the palatal cusps of the maxillary posterior teeth approximated the lingual cusps of the mandibular posterior teeth.~The expander was kept in place as a passive retainer for 8 months. After expander removal, patients were followed without performing any additional treatment for 4 months.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Banded RME (Rapid Maxillary Expander) appliance
Description: The expansion screw was activated 1 quarter of a turn per day (0.25 mm per turn) until the palatal cusps of the maxillary posterior teeth approximated the lingual cusps of the mandibular posterior teeth.~The expander was kept in place as a passive retainer for 8 months. After expander removal, patients were followed without performing any additional treatment for 4 months.
Study: NCT02335814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLX925
Study: NCT01831583

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Measurement of PPG waveforms
Description: The ViSi Vital Signs Monitor will measure PPG waveforms for 4 hours.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Measurement of Pulse Arrival Time (PAT)
Description: The ViSi Vital Signs Monitor will measure PAT waveforms for 4 hours.
Study: NCT03225040

Intervention type: DRUG
Intervention: Pegvisomant
Description: Subjects receiving pegvisomant as part of their clinical care for acromegaly will be studied.
Study: NCT01348477

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Elliptical domed mesh technique
Description: A segment of polypropylene mesh of 10 by 15cm enters the inguinal preperitoneal space, where takes the form of a dome and is fixed by four stitches

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Elliptical domed mesh technique
Description: A segment of polypropylene mesh of 10 by 15cm enters the inguinal preperitoneal space, where takes the form of a dome and is fixed by four stitches
Study: NCT02277561

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: diffusion tensor imaging
Description: Undergo VB-DTI

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: whole-brain radiation therapy
Description: Undergo WBRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic radiosurgery
Description: Undergo SRS

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: contrast-enhanced magnetic resonance imaging
Description: Undergo contrast-enhanced MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: diffusion-weighted magnetic resonance imaging
Description: Undergo DW MRI
Study: NCT02158429

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 2 dimensional vs. 3 dimensional ultrasound
Description: At the end of a regularly scheduled ultrasound measuring fetal growth an additional 5-10 minute ultrasound will be performed, either in 2-dimensional or 3-dimensional mode

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 2 dimensional vs. 3 dimensional ultrasound
Description: At the end of a regularly scheduled ultrasound measuring fetal growth an additional 5-10 minute ultrasound will be performed, either in 2-dimensional or 3-dimensional mode
Study: NCT02796417

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REHACOP
Description: REHACOP group consists of 90-minute-long sessions 3 days per week. Specifically, REHACOP group remediation consisted of: Attention unit (4 weeks) training sustained, selective, alternant and divided attention; Memory unit (3 weeks) focusing on visual and verbal learning, recall and recognizing memory; Language unit (3 weeks) including grammar, syntax, vocabulary, verbal fluency, verbal comprehension, abstract language; Executive functions unit (2 weeks) training cognitive planning, proverbs, analogies; and Social cognition unit (1 week) exercising theory of mind, social reasoning and moral dilemmas

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Occupational activities
Description: Occupational group activities conducted included drawing, gardening, reading the daily news and constructing using different materials (such as paper or wood).
Study: NCT03810872

Intervention type: DRUG
Group type: OTHER
Intervention: Afatinib
Description: Open label

Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel
Description: Paclitaxel
Study: NCT01947855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet matching Empagliflozin low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Empagliflozin low dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet matching Empagliflozin high dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet matching Empagliflozin low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Empagliflozin high dose tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet matching Empagliflozin high dose
Study: NCT02613273

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Arm 1 (Aerobic Exercise)
Description: This periodized program consists of 3 aerobic exercise sessions per week comprised of two high-intensity interval training workouts and 1 continuous vigorous intensity workout.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Arm 2 (Resist. Exercise)
Description: This periodized program consisting of 3 resistance exercise sessions per week comprised of high load/low volume, light load/high volume, and moderate load/moderate volume.
Study: NCT02282293

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monthly dihydroartemisinin-piperaquine (DP) + daily trimethoprim/sulfamethoxazole (TS)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Monthly placebo + daily trimethoprim/sulfamethoxazole (TS)
Study: NCT03927378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-ketamine
Description: S-ketamine (0.2 mg/kg in 20 ml normal saline) is administered by intravenous infusion in 40 minutes after childbirth.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (20 ml normal saline) is administered by intravenous infusion in 40 minutes after childbirth.